» Articles » PMID: 34369652

Bacterial Lysis, Autophagy and Innate Immune Responses During Adjunctive Phage Therapy in a Child

Abstract

Adjunctive phage therapy was used in an attempt to avoid catastrophic outcomes from extensive chronic Pseudomonas aeruginosa osteoarticular infection in a 7-year-old child. Monitoring of phage and bacterial kinetics allowed real-time phage dose adjustment, and along with markers of the human host response, indicated a significant therapeutic effect within two weeks of starting adjunctive phage therapy. These findings strongly suggested the release of bacterial cells or cell fragments into the bloodstream from deep bony infection sites early in treatment. This was associated with transient fever and local pain and with evidence of marked upregulation of innate immunity genes in the host transcriptome. Adaptive immune responses appeared to develop after a week of therapy and some immunomodulatory elements were also observed to be upregulated.

Citing Articles

Differences in Phage Recognition and Immunogenicity Contribute to Divergent Human Immune Responses to Escherichia coli and Klebsiella pneumoniae Phages.

Le H, Venturini C, Lubian A, Bowring B, Iredell J, George J Eur J Immunol. 2025; 55(3):e202451543.

PMID: 40071703 PMC: 11898580. DOI: 10.1002/eji.202451543.


Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.

Kim M, Suh G, Cullen G, Perez Rodriguez S, Dharmaraj T, Chang T J Clin Invest. 2025; 135(5).

PMID: 40026251 PMC: 11870740. DOI: 10.1172/JCI187996.


Emerging antimicrobial therapies for Gram-negative infections in human clinical use.

Hickson S, Ledger E, Wells T NPJ Antimicrob Resist. 2025; 3(1):16.

PMID: 40016340 PMC: 11868545. DOI: 10.1038/s44259-025-00087-2.


Phage therapy in the management of respiratory and pulmonary infections: a systematic review.

Sarkodie-Addo P, Osman A, Aglomasa B, Donkor E Ther Adv Infect Dis. 2025; 12:20499361241307841.

PMID: 39866829 PMC: 11760135. DOI: 10.1177/20499361241307841.


Phage Therapy Against Antibiotic-Resistant and Multidrug-Resistant Infections Involving Nonhealing Wounds and Prosthetic Joint Infections Associated With Biofilms: A Mini-Review.

Haq K, Figgitt M, Lee D Can J Infect Dis Med Microbiol. 2024; 2024:6252415.

PMID: 39545100 PMC: 11563716. DOI: 10.1155/2024/6252415.


References
1.
Jounai N, Takeshita F, Kobiyama K, Sawano A, Miyawaki A, Xin K . The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc Natl Acad Sci U S A. 2007; 104(35):14050-5. PMC: 1955809. DOI: 10.1073/pnas.0704014104. View

2.
Khawaldeh A, Morales S, Dillon B, Alavidze Z, Ginn A, Thomas L . Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J Med Microbiol. 2011; 60(Pt 11):1697-1700. DOI: 10.1099/jmm.0.029744-0. View

3.
Jackson J, KROPP H . beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis. 1992; 165(6):1033-41. DOI: 10.1093/infdis/165.6.1033. View

4.
Haedicke J, Brown C, Naghavi M . The brain-specific factor FEZ1 is a determinant of neuronal susceptibility to HIV-1 infection. Proc Natl Acad Sci U S A. 2009; 106(33):14040-5. PMC: 2729016. DOI: 10.1073/pnas.0900502106. View

5.
Petrovic Fabijan A, Lin R, Ho J, Maddocks S, Ben Zakour N, Iredell J . Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat Microbiol. 2020; 5(3):465-472. DOI: 10.1038/s41564-019-0634-z. View